{"Clinical Trial ID": "NCT00764322", "Intervention": ["INTERVENTION 1:", "Ultra-fast metabolizers", "Those with the greatest transformation of CYP2D6 genotype into allelic activity", "INTERVENTION 2:", "Widespread metabolizers", "Those with the most normal transformation of CYP2D6 genotype into allelic activity"], "Eligibility": ["Inclusion:", "A confirmed invasive invasive in situ carcinoma of the breast or canal carcinoma received tamoxifen citrate at a dose of 20 mg/day for at least 4 months, either for the treatment of invasive or non-invasive carcinoma of the breast or for the prevention of recurrence of breast cancer.", "Expected duration of tamoxifen citrate treatment at least 6 months Unspecified hormone receptor condition Simultaneous participation in non-treated studies allowed provided it does not interfere with participation in this study Status of unspecified menopause Performance status of the Eastern Cooperative Oncology Group (ECOG) 0-2 Life expectancy 6 months Absolute number of neutrophils (CNA) 1.0 x 109/L Number of platelets 100 x 10^9/L Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 2.5 times Upper limit of normal (ULN) Total bilirubin 2.5 times ULN creatinine clearance 50 mL/min Fertility patients should use effective contraception", "THERAPE PRIOR CONCURENT:", "No limit on the number of previous therapies", "No limit for prior radiation therapy", "More than 14 days since the previous one and no other competing search agent", "- Exclusion:", "No active infection, serious infection or medical or psychiatric illness likely to prevent participation in the study No psychiatric condition that would prevent compliance with the study or informed consent No history of venous thromboembolism, transient ischaemic attack or stroke No history of allergic reaction to tamoxifen citrate or any of its reagents No concomitant coumadine", "No concurrent medicinal products known to inhibit CYP2D6, including any of the following:", "- Amiodarone", "- Haloperidol", "Indinavir", "- Ritonavir", "Quinidine", "No concomitant selective serotonin reuptake inhibitors except:", "- Venlafaxine", "- Citalopram"], "Results": ["Performance measures:", "Endoxifene concentrations in participants receiving a dose of tamoxifen citrate of 20 mg or 40 mg Stratified by CYP2D6 genotypes metabolizing", "- Plasma concentrations of the major active metabolite of tamoxifen, endoxifene, were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles were grouped by functional activity classifications with descending activity: ultrafast (UM), extended metabolism (EM), intermediate (IM) or poor (PM). A given patient has two alleles, giving it 10 possible allelic combinations, or diplotypes (UM/UM, UM/EM, EM/EM, etc.). These diplotypes are collapsed into four phenotypes, UM, EM, IM or PM.", "Time limit: 4 months", "Results 1:", "Title of arm/group: Ultrafast metabolizers", "Description of the arm/group: Those with the strongest transformation of CYP2D6 genotype into allelic activity", "Total number of participants analysed: 5", "Average (standard deviation)", "Unit of measurement: reference endoxifene concentration in ng/mL: 5 participants", "- 8.4 (4.59)", "4 months endoxifene concentration: 4 participants", "15.35 (5.48)", "Results 2:", "Title of arm/group: Extended metabolizers", "Description of the arm/group: Those with the most normal transformation of the CYP2D6 genotype into allelic activity", "Total number of participants analysed: 119", "Average (standard deviation)", "Unit of measurement: reference endoxifene concentration in ng/mL: 119 participants", "10.00 (6.00)", "4-Month endoxifene concentration: 106 participants", "9.30 (5.03)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/161 (0.00 per cent)", "Headache * 20/161 (0.00 %)", "Change in mood 2 [1]0/161 (0.00 %)", "Haemorrhage, GU 0/161 (0.00 %)", "Thrombosis * 2 [2]0/161 (0.00 %)", "Adverse Events 2:", "Total: 3/290 (1.03 per cent)", "Headache * 21/290 (0.34%)", "2 [1]1/290 (0.34%)", "Haemorrhage, GU 1/290 (0.34%)", "Thrombosis * 2 [2]1/290 (0.34%)"]}